[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.

Original reporting
Published Oct 30, 2026, 5:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2026, 10:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ILMN
Bullish
high confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$ILMNBullishHigh
01

Why it matters

Guidance raise suggests sustained demand; investors may adjust positions accordingly.

02

Market read

Earnings beat and guidance lift are likely to move Illumina stock and influence the broader genomics sector.

03

What to watch

Potential regulatory headwinds in China and supply‑chain constraints could temper growth.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Illumina reported Q3 2026 results with revenue up 4.7% YoY and highlighted NovaSeq X placements.

Company-level read

Ticker impact

$ILMNBullishHigh confidence
Context

Illumina raised FY2026 revenue guidance to $4.64‑$4.66B and EPS to $5.40‑$5.45 after a Q3 beat.

Expected impact

upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Guidance raise of $30M at the midpoint and EPS beat indicate better-than-expected performance, prompting buying interest.

Market effects

Positive outlook for genomics sequencing sector, may lift peers with similar exposure.

Strengthens US biotech sentiment; modest impact on Asian markets.

Reinforces demand for clinical sequencing worldwide, especially in China.

Counterpoint

If guidance is overly optimistic, future quarters could miss expectations, leading to a pull‑back.

Key entities

  • Jacob Thaysen

    CEO of Illumina, provided commentary on demand and guidance.

  • Ankur Dhingra

    CFO of Illumina, discussed financials and future outlook.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

Illumina Inc (ILMN) Q3 2026 Earnings Call Highlights: Raised Guidance, Strong NovaSeq

Illumina (ILMN) raised FY2026 revenue guidance to $4.64-$4.66B and EPS to $5.40-$5.45, citing strong Q3 performance and higher consumables expectations. NovaSeq X placements exceeded 80 instruments in Q3, driving future revenue. Operating margin expanded to 25% in Q3, with 400bps improvement vs 2024 expected. Clinical sequencing consumables grew 14% YoY in Rest of World, while research consumables declined 6% YoY. Geopolitical uncertainties and pricing headwinds remain challenges.